Cargando…

A Functional Variant on 9p21.3 Related to Glioma Risk Affects Enhancer Activity and Modulates Expression of CDKN2B‐AS1

Genome‐wide association studies have identified SNPs associated with glioma risk on 9p21.3, but biological mechanisms underlying this association are unknown. We tested the hypothesis that a functional SNP on 9p21.3 affects activity of an enhancer, causing altered expression of nearby genes. We cons...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Mourad Wagdy, Patro, C. Pawan K., Devall, Matthew, Dampier, Christopher H., Plummer, Sarah J., Kuscu, Cem, Adli, Mazhar, Lai, Rose K., Casey, Graham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519084/
https://www.ncbi.nlm.nih.gov/pubmed/34153138
http://dx.doi.org/10.1002/humu.24244
_version_ 1784584376764334080
author Ali, Mourad Wagdy
Patro, C. Pawan K.
Devall, Matthew
Dampier, Christopher H.
Plummer, Sarah J.
Kuscu, Cem
Adli, Mazhar
Lai, Rose K.
Casey, Graham
author_facet Ali, Mourad Wagdy
Patro, C. Pawan K.
Devall, Matthew
Dampier, Christopher H.
Plummer, Sarah J.
Kuscu, Cem
Adli, Mazhar
Lai, Rose K.
Casey, Graham
author_sort Ali, Mourad Wagdy
collection PubMed
description Genome‐wide association studies have identified SNPs associated with glioma risk on 9p21.3, but biological mechanisms underlying this association are unknown. We tested the hypothesis that a functional SNP on 9p21.3 affects activity of an enhancer, causing altered expression of nearby genes. We considered all SNPs in linkage disequilibrium with the 9p21.3 sentinel SNP rs634537 that mapped to putative enhancers. An enhancer containing rs1537372 exhibited allele‐specific effects on luciferase activity. Deletion of this enhancer in GBM cell lines correlated with decreased expression of CDKN2B‐AS1. Expression quantitative trait loci analysis using non‐diseased brain samples showed rs1537372 to be a consistently significant eQTL for CDKN2B‐AS1. Additionally, our analysis of Hi‐C data generated in neural progenitor cells showed that the bait region containing rs1537372 interacted with the CDKN2B‐AS1 promoter. These data suggest rs1537372, a SNP at the 9p21.3 risk locus, is a functional variant that modulates expression of CDKN2B‐AS1.
format Online
Article
Text
id pubmed-8519084
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85190842021-10-22 A Functional Variant on 9p21.3 Related to Glioma Risk Affects Enhancer Activity and Modulates Expression of CDKN2B‐AS1 Ali, Mourad Wagdy Patro, C. Pawan K. Devall, Matthew Dampier, Christopher H. Plummer, Sarah J. Kuscu, Cem Adli, Mazhar Lai, Rose K. Casey, Graham Hum Mutat Brief Reports Genome‐wide association studies have identified SNPs associated with glioma risk on 9p21.3, but biological mechanisms underlying this association are unknown. We tested the hypothesis that a functional SNP on 9p21.3 affects activity of an enhancer, causing altered expression of nearby genes. We considered all SNPs in linkage disequilibrium with the 9p21.3 sentinel SNP rs634537 that mapped to putative enhancers. An enhancer containing rs1537372 exhibited allele‐specific effects on luciferase activity. Deletion of this enhancer in GBM cell lines correlated with decreased expression of CDKN2B‐AS1. Expression quantitative trait loci analysis using non‐diseased brain samples showed rs1537372 to be a consistently significant eQTL for CDKN2B‐AS1. Additionally, our analysis of Hi‐C data generated in neural progenitor cells showed that the bait region containing rs1537372 interacted with the CDKN2B‐AS1 promoter. These data suggest rs1537372, a SNP at the 9p21.3 risk locus, is a functional variant that modulates expression of CDKN2B‐AS1. John Wiley and Sons Inc. 2021-06-29 2021-10 /pmc/articles/PMC8519084/ /pubmed/34153138 http://dx.doi.org/10.1002/humu.24244 Text en © 2021 The Authors. Human Mutation Published by Wiley Periodicals LLC https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Brief Reports
Ali, Mourad Wagdy
Patro, C. Pawan K.
Devall, Matthew
Dampier, Christopher H.
Plummer, Sarah J.
Kuscu, Cem
Adli, Mazhar
Lai, Rose K.
Casey, Graham
A Functional Variant on 9p21.3 Related to Glioma Risk Affects Enhancer Activity and Modulates Expression of CDKN2B‐AS1
title A Functional Variant on 9p21.3 Related to Glioma Risk Affects Enhancer Activity and Modulates Expression of CDKN2B‐AS1
title_full A Functional Variant on 9p21.3 Related to Glioma Risk Affects Enhancer Activity and Modulates Expression of CDKN2B‐AS1
title_fullStr A Functional Variant on 9p21.3 Related to Glioma Risk Affects Enhancer Activity and Modulates Expression of CDKN2B‐AS1
title_full_unstemmed A Functional Variant on 9p21.3 Related to Glioma Risk Affects Enhancer Activity and Modulates Expression of CDKN2B‐AS1
title_short A Functional Variant on 9p21.3 Related to Glioma Risk Affects Enhancer Activity and Modulates Expression of CDKN2B‐AS1
title_sort functional variant on 9p21.3 related to glioma risk affects enhancer activity and modulates expression of cdkn2b‐as1
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519084/
https://www.ncbi.nlm.nih.gov/pubmed/34153138
http://dx.doi.org/10.1002/humu.24244
work_keys_str_mv AT alimouradwagdy afunctionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1
AT patrocpawank afunctionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1
AT devallmatthew afunctionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1
AT dampierchristopherh afunctionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1
AT plummersarahj afunctionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1
AT kuscucem afunctionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1
AT adlimazhar afunctionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1
AT lairosek afunctionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1
AT caseygraham afunctionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1
AT alimouradwagdy functionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1
AT patrocpawank functionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1
AT devallmatthew functionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1
AT dampierchristopherh functionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1
AT plummersarahj functionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1
AT kuscucem functionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1
AT adlimazhar functionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1
AT lairosek functionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1
AT caseygraham functionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1